This statistic shows the number of registrations of newly diagnosed cases of pancreatic cancer in England in 2022, by age group and gender. In this year, 902 cases of pancreatic cancer were reported among men aged 75 to 79 years. It should, of course, be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to pancreatic cancer.

In 2022, the rate of newly diagnosed pancreatic cancer cases in England was 20 per 100,000 for males and 16 per 100,000 for females. This represented a considerable increase in the rate of newly diagnosed cases for females compared to the previous year. This statistic shows the rate of newly diagnosed cases of pancreatic cancer per 100,000 population in England from 1995 to 2022, by gender.

BackgroundTo estimate the global burden of pancreatic cancer in 2019 and 2021 including incidence, mortality, and disability-adjusted-life-years (DALYs).MethodsData on pancreatic cancer incidence, mortality and DALYs were downloaded from the Global Health Data Exchange. The 95% uncertainty intervals (UIs) were reported for annual numbers and rates (per 100,000 populations).ResultsIn 2021, there were 508,532 (95% UI: 462,09 to 547,208) incident cases of pancreatic cancer globally, of which 273,617 (250,808 to 299,347; 53.8%) were in males. The age-standardized incidence rate was 6.0 (5.5 to 6.5) per 100,000 people in 2019 and decreased to 5.9 (5.4 to 6.4) per 100,000 people in 2021. There was a 3.9% increase in the number of deaths from pancreatic cancer from 486,869 (446,272 to 517,185) in 2019 to 505,752 (461,224 to 543,899) in 2021. There was a 3.5% increase in DALYs due to pancreatic cancer, increasing from 10.9 million (10.1 to 11.7) in 2019 to 11.3 million (10.5 to 12.2) in 2021. In 2021, the highest age-standardized death rates were observed in Greenland and Monaco, and the highest age-standardized DALY rates were observed in Greenland and Uruguay. The numbers of incident cases and deaths peaked at the ages of 70 to 74 years. The pancreatic cancer burden increased as the socio-demographic index increased. To 2044, the number of incident cases and deaths will be more than 875 thousand and 879 thousand, respectively.ConclusionThe disease burden of pancreatic cancer remains high, especially in high-income regions. More cancer prevention measures are needed in the future to reduce the burden of pancreatic cancer.

In Germany, the number of pancreatic cancer cases decreased slightly from 2019 to 2022 for both men and women, with over ************* cases reported for both genders in 2022. This statistic depicts the number of pancreatic cancer cases in Germany between 2019 and 2022, by gender.

This statistic illustrates the number of deaths due to pancreas cancer in the United States from 1999 to 2021. The highest number of deaths due to pancreas cancer was ****** reported in 2021.

A previous meta-analysis suggested no association between fish consumption and risk of pancreatic cancer. As several prospective studies with a large number of pancreatic cancer cases have emerged after that meta-analysis, we updated the evidence and examined the relationship in greater depth. We performed a literature search on PubMed and EMBASE databases through March 30, 2019 to identify potentially eligible studies. We used a random-effects model to compute summary relative risk (RR) with corresponding 95% confidence interval (CI). A total of 13 prospective studies comprising 4994 pancreatic cancer cases and 1,794,601 participants were included in the final analyses. Results of the meta-analysis showed that fish consumption was not significantly associated with risk of pancreatic cancer (RR 50-g/day = 1.03, 95% CI: 0.95–1.12), which was confirmed when stratifying the analysis by various methodological and population characteristics. There was a suggestion of difference by adjustment for family history of pancreatic cancer (Pdifference = 0.05), with fish consumption being associated with higher risk of pancreatic cancer in studies without adjustment for participants’ family history (RR50-g/day = 1.09, 95% CI: 1.02–1.18), and a non-significant inverse association among studies with the adjustment (RR50-g/day = 0.93, 95% CI: 0.82–1.05). Results of this updated meta-analysis suggest that fish consumption is unlikely to be substantially associated with risk of pancreatic cancer.

In 2024, the number of breast cancer cases among women in Japan reached approximately 91,100, which made it the most common type of cancer for women. The estimated total number of cancer cases for Japanese women in that year amounted to almost 421,000. Most common types of cancer in Japan Following breast cancer, colon and rectum, lung, as well as stomach were the most frequently diagnosed cancer sites among women in Japan. In contrast, prostate cancer was the most frequently diagnosed cancer among men, followed by stomach, colon and rectum, and lung cancer.Different types of cancer rank among the most common causes of death among Japanese people. In terms of cancer-related mortality among women in Japan, lung cancer claimed the highest number of lives in recent years, followed by pancreatic cancer.  Prevention and treatment of breast cancer In recent years, colon, cervix, lung, breast, and stomach were the most common cancer sites for screening in Japan. This was supported by a survey from 2023, in which over 36 percent of Japanese women stated that they had a cancer screening in the past two years.More attention has been given to breast cancer treatment as the incidence of breast cancer in Japan has grown throughout the past decades. Consequently, the number of general hospitals equipped with breast surgery departments increased as well.The early detection of breast cancer is crucial to increase the chance of survival. The primary approach to breast cancer treatment involves surgical removal of the cancer, though preoperative drug therapy may be administered based on the cancer's condition.

Although the link between sugar-sweetened beverages (SSB) and pancreatic cancer has been suggested for its insulin-stimulating connection, most epidemiological studies showed inconclusive relationship. Whether the result was limited by sample size is explored. This prospective study followed 491,929 adults, consisting of 235,427 men and 256,502 women (mean age: 39.9, standard deviation: 13.2), from a health surveillance program and there were 523 pancreatic cancer deaths between 1994 and 2017. The individual identification numbers of the cohort were matched with the National Death file for mortality, and Cox models were used to assess the risk. The amount of SSB intake was recorded based on the average consumption in the month before interview by a structured questionnaire. We classified the amount of SSB intake into 4 categories: 0–

Basic Metadata *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

Pancreatic Cancer Diagnostics Market Outlook

According to our latest research, the global pancreatic cancer diagnostics market size reached USD 4.8 billion in 2024, with a robust compound annual growth rate (CAGR) of 7.2% expected from 2025 to 2033. By the end of 2033, the market is forecasted to attain a value of USD 9.1 billion, driven by a confluence of rising pancreatic cancer incidence, technological advancements in diagnostic modalities, and increasing awareness regarding early detection. The growth of this market is underpinned by continuous innovation in molecular diagnostics and biomarker research, alongside a heightened focus on improving patient outcomes through early and accurate diagnosis.

One of the primary growth factors for the pancreatic cancer diagnostics market is the increasing global incidence and mortality associated with pancreatic cancer. Pancreatic cancer is notorious for its poor prognosis and high fatality rate, largely due to its asymptomatic nature in early stages and the lack of effective early screening tools. As a result, there is a significant unmet need for more sensitive and specific diagnostic technologies. The aging global population and higher prevalence of risk factors such as smoking, obesity, and diabetes further contribute to the rising number of pancreatic cancer cases. This epidemiological trend is compelling healthcare providers and governments to invest in advanced diagnostic solutions, fostering a favorable environment for market expansion.

Technological advancements represent another pivotal growth driver for the pancreatic cancer diagnostics market. The integration of next-generation sequencing (NGS), liquid biopsy, and advanced imaging modalities has revolutionized the landscape of cancer diagnostics. These innovations have enhanced the sensitivity and specificity of pancreatic cancer detection, enabling earlier diagnosis and more personalized treatment strategies. Additionally, the development of novel biomarkers for pancreatic cancer has facilitated the emergence of non-invasive and minimally invasive diagnostic tests, which are increasingly being adopted in clinical practice. The ongoing research and development activities in molecular diagnostics and bioinformatics are expected to further accelerate the adoption of cutting-edge diagnostic tools in the coming years.

Government initiatives and increased funding for cancer research also play a significant role in propelling the pancreatic cancer diagnostics market forward. Several countries are implementing national cancer control programs and screening guidelines to improve early detection rates and reduce the disease burden. Public-private partnerships, grants, and collaborations between research institutes and industry players are driving the development and commercialization of innovative diagnostic products. Furthermore, rising awareness campaigns and patient advocacy efforts are encouraging individuals to seek timely medical attention, thereby boosting the demand for diagnostic services. Collectively, these factors are creating a supportive ecosystem for sustained market growth over the forecast period.

From a regional perspective, North America continues to dominate the pancreatic cancer diagnostics market, owing to its well-established healthcare infrastructure, high healthcare expenditure, and strong presence of leading diagnostic companies. Europe follows closely, driven by increasing investments in cancer research and the adoption of advanced diagnostic technologies. The Asia Pacific region is poised for the fastest growth, fueled by rising cancer prevalence, improving healthcare access, and growing investments in healthcare infrastructure. Emerging economies in Latin America and the Middle East & Africa are also witnessing steady market growth, supported by government initiatives and increasing awareness about the importance of early cancer detection.

Product Type Analysis

The product type segment of the pancreatic cancer diagnostics market encompasses imaging tests, biomarker tests, biopsy, molecular diagnostics, and other diagnostic modalities. Imaging tests, including computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound (EUS), represent a cornerstone of pancreatic cancer diagnostics, particularly for initial detection and staging. These modalities are widely adopted due to their ability to provide detailed anatom

Machine learning and semantic analysis are computer-based methods to evaluate complex relationships and predict future perspectives. We used these technologies to define recent, current and future topics in pancreatic cancer research. Publications indexed under the Medical Subject Headings (MeSH) term ‘Pancreatic Neoplasms’ from January 1996 to October 2021 were downloaded from PubMed. Using the statistical computing language R and the interpreted, high-level, general-purpose programming language Python, we extracted publication dates, geographic information, and abstracts from each publication’s metadata for bibliometric analyses. The generative statistical algorithm “latent Dirichlet allocation” (LDA) was applied to identify specific research topics and trends. The unsupervised “Louvain algorithm” was used to establish a network to identify relationships between single topics. A total of 60,296 publications were identified and analyzed. The publications were derived from 133 countries, mostly from the Northern Hemisphere. For the term “pancreatic cancer research”, 12,058 MeSH terms appeared 1,395,060 times. Among them, we identified the four main topics “Clinical Manifestation and Diagnosis”, “Review and Management”, “Treatment Studies”, and “Basic Research”. The number of publications has increased rapidly during the past 25 years. Based on the number of publications, the algorithm predicted that “Immunotherapy”, Prognostic research”, “Protein expression”, “Case reports”, “Gemcitabine and mechanism”, “Clinical study of gemcitabine”, “Operation and postoperation”, “Chemotherapy and resection”, and “Review and management” as current research topics. To our knowledge, this is the first study on this subject of pancreatic cancer research, which has become possible due to the improvement of algorithms and hardware.

In 2022, the number of deaths from pancreatic cancer in Spain reached approximately 8,000 cases. This figure showed an upward trend since 2006, when the number of casualties caused by pancreatic cancer amounted to around 4,800 in the European country. In the last year depicted, 92 pancreas transplants had been performed in Spain.

Background Regular use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been consistently associated with reduced risk of colorectal cancer and adenoma, and there is some evidence for a protective effect for other types of cancer. As experimental studies reveal a possible role for NSAIDs is reducing the risk of pancreatic cancer, epidemiological studies examining similar associations in human populations become more important. Methods In this hospital-based case-control study, 194 patients with pancreatic cancer were compared to 582 age and sex-matched patients with non-neoplastic conditions to examine the association between aspirin use and risk of pancreatic cancer. All participants received medical services at the Roswell Park Cancer Institute in Buffalo, NY and completed a comprehensive epidemiologic questionnaire that included information on demographics, lifestyle factors and medical history as well as frequency and duration of aspirin use. Patients using at least one tablet per week for at least six months were classified as regular aspirin users. Unconditional logistic regression was used to compute crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Results Pancreatic cancer risk in aspirin users was not changed relative to non-users (adjusted OR = 1.00; 95% CI 0.72–1.39). No significant change in risk was found in relation to greater frequency or prolonged duration of use, in the total sample or in either gender. Conclusions These data suggest that regular aspirin use may not be associated with lower risk of pancreatic cancer.

Genome-wide association studies (GWASs) have identified many single nucleotide polymorphisms (SNPs) that are significantly associated with pancreatic cancer susceptibility. We sought to replicate the associations of 61 GWAS-identified SNPs at 42 loci with pancreatic cancer in Japanese and to develop a risk model for the identification of individuals at high risk for pancreatic cancer development in the general Japanese population. The model was based on data including directly determined or imputed SNP genotypes for 664 pancreatic cancer case and 664 age- and sex-matched control subjects. Stepwise logistic regression uncovered five GWAS-identified SNPs at five loci that also showed significant associations in our case-control cohort. These five SNPs were included in the risk model and also applied to calculation of the polygenic risk score (PRS). The area under the curve determined with the leave-one-out cross-validation method was 0.63 (95% confidence interval, 0.60–0.66) or 0.61 (0.58–0.64) for versions of the model that did or did not include cigarette smoking and family history of pancreatic cancer in addition to the five SNPs, respectively. Individuals in the lowest and highest quintiles for the PRS had odds ratios of 0.62 (0.42–0.91) and 1.98 (1.42–2.76), respectively, for pancreatic cancer development compared with those in the middle quintile. We have thus developed a risk model for pancreatic cancer that showed moderately good discriminatory ability with regard to differentiation of pancreatic cancer patients from control individuals. Our findings suggest the potential utility of a risk model that incorporates replicated GWAS-identified SNPs and established demographic or environmental factors for the identification of individuals at increased risk for pancreatic cancer development.

BackgroundThe relationship between red and processed meat consumption and pancreatic cancer risk is controversial and no study has looked specifically at the correlation for 6 years. We conducted a meta-analysis to summarize the evidence about the association between them.MethodsWe systematically searched PubMed, Embase and Cochrane Library for studies of red or processed meat consumption and pancreatic cancer published from December 2016 to July 2022. We performed random-effects models to pool the relative risks from individual studies. Subgroup analyses were used to figure out heterogeneity. We also performed publication bias analysis.ResultsSeven cohort studies and one case–control study that contained a total of 7,158 pancreatic cancer cases from 805,177 participants were eligible for inclusion. The combined RRs (95% CI) comparing highest and lowest categories were 1.07 (95% CI: 0.91–1.26; p = 0.064) for red meat and 1.04 (95% CI: 0.81–1.33; p = 0.006) for processed meat with statistically significant heterogeneity.ConclusionThis meta-analysis suggested that red and processed meat consumption has no relationship with pancreatic cancer risk.

This is a carefully curated dataset of patients who have either been diagnosed with Pancreatic Cancer (PC) or are deemed high risk. Sourced from Manchester Foundation Trust systems, the dataset was curated for use in a predictive model.

Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

According to our latest research, the global pancreatic cancer therapeutics & diagnostics market size reached USD 5.8 billion in 2024. The market is exhibiting a robust growth trajectory, with a CAGR of 9.3% forecasted from 2025 to 2033. By the end of 2033, the market is expected to reach approximately USD 13.2 billion. This impressive growth is primarily driven by the increasing incidence of pancreatic cancer worldwide, coupled with advancements in both therapeutic and diagnostic modalities that are improving patient outcomes and survival rates.

One of the key growth factors fueling the expansion of the pancreatic cancer therapeutics & diagnostics market is the rising global burden of pancreatic cancer. The disease remains one of the most lethal malignancies, with a five-year survival rate still below 10%. The growing geriatric population, which is more susceptible to cancer, alongside lifestyle changes such as increased tobacco use, obesity, and diabetes, has led to a surge in pancreatic cancer cases. This, in turn, is driving demand for innovative diagnostic techniques and more effective therapeutic options. Additionally, heightened awareness among patients and healthcare providers, as well as government initiatives to improve cancer care infrastructure, are bolstering early detection and treatment rates, further propelling market growth.

Another significant factor contributing to market expansion is the technological innovation in both diagnostics and therapeutics. The introduction of advanced imaging modalities, liquid biopsies, and molecular diagnostics has revolutionized the early detection of pancreatic cancer. These technologies enable more accurate and less invasive diagnosis, which is critical for a disease often detected at an advanced stage. On the therapeutics front, the development of targeted therapies and immunotherapies is providing new hope for patients who previously had limited treatment options. Pharmaceutical companies are investing heavily in research and development, leading to a robust pipeline of novel drugs and diagnostic tools that are expected to enter the market over the forecast period.

The market is also experiencing growth due to increasing collaborations between research institutes, pharmaceutical companies, and diagnostic laboratories. These partnerships are accelerating the translation of scientific discoveries into clinically viable products. The rise in clinical trials, especially in emerging markets, is facilitating access to innovative treatments for larger patient populations. Furthermore, the growing trend of personalized medicine, which leverages genetic and molecular profiling to tailor therapies, is gaining traction in pancreatic cancer care. This approach not only enhances treatment efficacy but also minimizes adverse effects, thereby improving patient quality of life and driving adoption of advanced therapeutics and diagnostics.

In the realm of cancer diagnostics and therapeutics, ovarian cancer stands as a significant area of focus, much like pancreatic cancer. Ovarian Cancer Diagnostics and Therapeutics have seen substantial advancements, particularly with the integration of genetic testing and personalized medicine approaches. These innovations are enhancing early detection and treatment efficacy, offering hope for improved survival rates. The parallels between the challenges faced in ovarian and pancreatic cancer management highlight the importance of continued research and development in these fields. By leveraging insights from one area, we can potentially accelerate progress in the other, ultimately benefiting a broader patient population.

From a regional perspective, North America currently dominates the pancreatic cancer therapeutics & diagnostics market, accounting for the largest revenue share in 2024. This is attributed to the presence of a well-established healthcare infrastructure, high healthcare expenditure, and significant investments in cancer research. Europe follows closely, driven by government support for cancer screening programs and a strong focus on early detection. The Asia Pacific region is expected to witness the fastest growth over the forecast period, fueled by rising cancer incidence, increasing heal

Can a simple urine test detect one of the deadliest cancers? About Dataset This is a brand-new (!) dataset from an open-access paper published December 10, 2020. The paper and the full dataset are open-access (CC-BY), so please give attribution to the original authors in your work. Background Pancreatic cancer is an extremely deadly type of cancer. Once diagnosed, the five-year survival rate is less than 10%. However, if pancreatic cancer is caught early, the odds of surviving are much better. Unfortunately, many cases of pancreatic cancer show no symptoms until the cancer has spread throughout the body. A diagnostic test to identify people with pancreatic cancer could be enormously helpful. The paper In a paper by Silvana Debernardi and colleagues, published this year in the journal PLOS Medicine, a multi-national team of researchers sought to develop an accurate diagnostic test for the most common type of pancreatic cancer, called pancreatic ductal adenocarcinoma or PDAC. They gathered a series of biomarkers from the urine of three groups of patients: Healthy controls Patients with non-cancerous pancreatic conditions, like chronic pancreatitis Patients with pancreatic ductal adenocarcinoma When possible, these patients were age- and sex-matched. The goal was to develop an accurate way to identify patients with pancreatic cancer. The data The key features are four urinary biomarkers: creatinine, LYVE1, REG1B, and TFF1. Creatinine is a protein that is often used as an indicator of kidney function. YVLE1 is lymphatic vessel endothelial hyaluronan receptor 1, a protein that may play a role in tumor metastasis REG1B is a protein that may be associated with pancreas regeneration TFF1 is trefoil factor 1, which may be related to regeneration and repair of the urinary tract Age and sex, both included in the dataset, may also play a role in who gets pancreatic cancer. The dataset includes a few other biomarkers as well, but these were not measured in all patients (they were collected partly to measure how various blood biomarkers compared to urine biomarkers). I have not changed any of the data from the paper, other than renaming the columns for easy importing and use. The file Debernardi et al 2020 data.csv contains the raw data, while the file Debernardi et al 2020 documentation.csv contains a detailed documentation of what each column represents (as well as the original column names from the paper). Prediction task The goal in this dataset is predicting diagnosis, and more specifically, differentiating between 3 (pancreatic cancer) versus 2 (non-cancerous pancreas condition) and 1 (healthy). The dataset includes information on stage of pancreatic cancer, and diagnosis for non-cancerous patients, but remember—these won't be available to a predictive model. The goal, after all, is to predict the presence of disease before it's diagnosed, not after! Acknowledgements I would like to thank the authors of this paper, for graciously sharing their raw data with the research community.

Pancreatic cancer is an extremely deadly type of cancer. Once diagnosed, the five-year survival rate is less than 10%. However, if pancreatic cancer is caught early, the odds of surviving are much better. Unfortunately, many cases of pancreatic cancer show no symptoms until the cancer has spread throughout the body. A diagnostic test to identify people with pancreatic cancer could be enormously helpful.

Background and objectiveEarly detection methods for pancreatic cancer are lacking. We aimed to develop a prediction model for pancreatic cancer based on changes in health captured by healthcare claims data.MethodsWe conducted a case-control study on 29,646 Medicare-enrolled patients aged 68 years and above with pancreatic ductal adenocarcinoma (PDAC) reported to the Surveillance Epidemiology an End Results (SEER) tumor registries program in 2004–2011 and 88,938 age and sex-matched controls. We developed a prediction model using multivariable logistic regression on Medicare claims for 16 risk factors and pre-diagnostic symptoms of PDAC present within 15 months prior to PDAC diagnosis. Claims within 3 months of PDAC diagnosis were excluded in sensitivity analyses. We evaluated the discriminatory power of the model with the area under the receiver operating curve (AUC) and performed cross-validation by bootstrapping.ResultsThe prediction model on all cases and controls reached AUC of 0.68. Excluding the final 3 months of claims lowered the AUC to 0.58. Among new-onset diabetes patients, the prediction model reached AUC of 0.73, which decreased to 0.63 when claims from the final 3 months were excluded. Performance measures of the prediction models was confirmed by internal validation using the bootstrap method.ConclusionModels based on healthcare claims for clinical risk factors, symptoms and signs of pancreatic cancer are limited in classifying those who go on to diagnosis of pancreatic cancer and those who do not, especially when excluding claims that immediately precede the diagnosis of PDAC.